Nothing Special   »   [go: up one dir, main page]

BR112019021853A2 - Compostos de inibidor de vmat2 e composições dos mesmos - Google Patents

Compostos de inibidor de vmat2 e composições dos mesmos Download PDF

Info

Publication number
BR112019021853A2
BR112019021853A2 BR112019021853-0A BR112019021853A BR112019021853A2 BR 112019021853 A2 BR112019021853 A2 BR 112019021853A2 BR 112019021853 A BR112019021853 A BR 112019021853A BR 112019021853 A2 BR112019021853 A2 BR 112019021853A2
Authority
BR
Brazil
Prior art keywords
compounds
compositions
same
inhibitor compounds
vmat2 inhibitor
Prior art date
Application number
BR112019021853-0A
Other languages
English (en)
Inventor
Harriott Nicole
Nicholas Hettinger Donald
Branum Shawn
C. Culhane Jeffrey
Original Assignee
Neurocrine Biosciences Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62111264&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112019021853(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurocrine Biosciences Inc. filed Critical Neurocrine Biosciences Inc.
Publication of BR112019021853A2 publication Critical patent/BR112019021853A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

é fornecido um composto selecionado de compostos de fórmula (i) e hidratos, solvatos e sais farmaceuticamente aceitáveis do mesmo: (i) em que r1, r2, r3 e r4 são como definidos aqui. tais compostos são inibidores do transportados da monoamina vesicular 2 (vmat2) e têm utilidade para o tratamento, por exemplo, doenças e distúrbios neurológicos e psiquiátricos. são também descritas composições contendo tais compostos em combinação com um veículo farmaceuticamente aceitável, bem como os métodos relacionados ao seu uso em indivíduos em necessidade dos mesmos.
BR112019021853-0A 2017-04-19 2018-04-17 Compostos de inibidor de vmat2 e composições dos mesmos BR112019021853A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762487413P 2017-04-19 2017-04-19
US62/487,413 2017-04-19
US201862652837P 2018-04-04 2018-04-04
US62/652,837 2018-04-04
PCT/US2018/028031 WO2018195121A1 (en) 2017-04-19 2018-04-17 Vmat2 inhibitor compounds and compositions thereof

Publications (1)

Publication Number Publication Date
BR112019021853A2 true BR112019021853A2 (pt) 2020-05-26

Family

ID=62111264

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019021853-0A BR112019021853A2 (pt) 2017-04-19 2018-04-17 Compostos de inibidor de vmat2 e composições dos mesmos

Country Status (17)

Country Link
US (1) US11040970B2 (pt)
EP (1) EP3612532B1 (pt)
JP (1) JP7170662B2 (pt)
KR (1) KR20190140968A (pt)
CN (1) CN110770236B (pt)
AU (1) AU2018254429A1 (pt)
BR (1) BR112019021853A2 (pt)
CA (1) CA3060251A1 (pt)
CL (1) CL2019002919A1 (pt)
CO (1) CO2019011604A2 (pt)
ES (1) ES2971230T3 (pt)
JO (1) JOP20190239A1 (pt)
MA (1) MA50145A (pt)
MX (1) MX2019012336A (pt)
PE (1) PE20191784A1 (pt)
TW (1) TW201841913A (pt)
WO (1) WO2018195121A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110740731A (zh) 2017-01-27 2020-01-31 纽罗克里生物科学有限公司 施用某些vmat2抑制剂的方法
JP7250006B2 (ja) 2017-09-21 2023-03-31 ニューロクライン バイオサイエンシーズ,インコーポレイテッド 高投与量バルベナジン製剤ならびにそれに関連する組成物、方法およびキット
JP2021502959A (ja) 2017-10-10 2021-02-04 ニューロクライン バイオサイエンシーズ,インコーポレイテッド 特定のvmat2インヒビターを投与するための方法
JP2021528386A (ja) * 2018-06-14 2021-10-21 ニューロクライン バイオサイエンシーズ,インコーポレイテッド Vmat2インヒビター化合物、上記化合物に関する組成物および方法
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
WO2020086765A1 (en) * 2018-10-24 2020-04-30 Neurocrine Biosciences, Inc. Processes for preparing a vmat2 inhibitor
IL292524A (en) 2019-11-11 2022-06-01 Incyte Corp Salts and crystalline forms of pd-1/pd-l1 inhibitor
BR112023016273A2 (pt) 2021-03-22 2023-10-03 Neurocrine Biosciences Inc Inibidores de vmat2 e métodos de uso
WO2022232380A1 (en) 2021-04-29 2022-11-03 Neurocrine Biosciences, Inc. Processes for preparing a vmat2 inhibitor
TW202322816A (zh) 2021-08-20 2023-06-16 美商紐羅克里生物科學有限公司 篩選 vmat2 抑制劑之方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
GB0106177D0 (en) 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
CA2528784C (en) 2003-06-20 2012-02-21 Markus Boehringer Hexahydropyridoisoquinolines as dpp-iv inhibitors
JP2008509925A (ja) 2004-08-13 2008-04-03 オメロス コーポレイション 新規のセロトニンレセプターリガンドおよびそれらの使用
CN101553487B (zh) 2006-11-08 2012-06-13 纽罗克里生物科学有限公司 取代的3-异丁基-9,10-二甲氧基-1,3,4,6,7,11b-六氢-2H-吡啶并[2,1-a]异喹啉-2-醇化合物和与其相关的方法
FR2912145B1 (fr) 2007-02-02 2009-03-06 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2009126305A1 (en) 2008-04-11 2009-10-15 The Trustees Of Columbia University Glucose metabolism modulating compounds
NO3061760T3 (pt) 2008-09-18 2018-04-07
WO2011075699A2 (en) 2009-12-18 2011-06-23 Sunovion Pharmaceuticals Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
CN102285984B (zh) 2010-11-25 2012-10-10 江苏威凯尔医药科技有限公司 (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
WO2014043866A1 (zh) 2012-09-19 2014-03-27 中国科学院福建物质结构研究所 噻吩[2,3-d]嘧啶衍生物、其制备方法及其用途
MX2016010071A (es) 2014-02-07 2017-04-27 Neurocrine Biosciences Inc Composiciones farmaceuticas que comprenden un farmaco antipsicotico y un inhibidor de la isoforma 2 del transportador de monomina vesicular (vmat2) y sus usos.
KR102586138B1 (ko) 2015-02-06 2023-10-05 뉴로크린 바이오사이언시즈 인코퍼레이티드 [9,10-디메톡시-3-(2-메틸프로필)-1H,2H,3H,4H,6H,7H,11bH-피리도-[2,1-a]이소퀴놀린-2-일]메탄올 및 그와 관련된 화합물, 조성물 및 방법
UA126394C2 (uk) 2016-12-22 2022-09-28 Інсайт Корпорейшн Похідні бензоксазолу як імуномодулятори
TWI798192B (zh) 2016-12-22 2023-04-11 美商英塞特公司 免疫調節劑化合物及使用方法

Also Published As

Publication number Publication date
CL2019002919A1 (es) 2020-01-17
CO2019011604A2 (es) 2019-10-31
ES2971230T3 (es) 2024-06-04
TW201841913A (zh) 2018-12-01
CA3060251A1 (en) 2018-10-25
JP2020517607A (ja) 2020-06-18
JOP20190239A1 (ar) 2019-10-09
PE20191784A1 (es) 2019-12-24
MA50145A (fr) 2020-07-29
EP3612532A1 (en) 2020-02-26
US20200131173A1 (en) 2020-04-30
US11040970B2 (en) 2021-06-22
MX2019012336A (es) 2020-07-14
AU2018254429A1 (en) 2019-11-07
CN110770236A (zh) 2020-02-07
JP7170662B2 (ja) 2022-11-14
EP3612532C0 (en) 2023-12-13
KR20190140968A (ko) 2019-12-20
WO2018195121A1 (en) 2018-10-25
CN110770236B (zh) 2023-03-24
EP3612532B1 (en) 2023-12-13

Similar Documents

Publication Publication Date Title
BR112019021853A2 (pt) Compostos de inibidor de vmat2 e composições dos mesmos
BR112019002610A2 (pt) piridopirimidinonas inibidoras de cdk2/4/6
UY37795A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
BR112014006660A2 (pt) novos derivados de dihidroquinolina-2-ona bicíclicos
AR088226A1 (es) Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
ECSP109958A (es) Derivados de pirimidina 934
MX2019006843A (es) Inhibidor de cdk4/6.
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
NI200900181A (es) Nuevos compuestos heterocíclicos nitrogenados, su preparación y su utilización como medicamentos antibacterianos.
RS52613B (en) CARBAMOIL-CYCLOHEXANES FOR THE TREATMENT OF ACUTE MANIA
UY37764A (es) Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds)
CU20210023A7 (es) Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4
ECSP21011232A (es) Nuevo derivado de amina heterocíclico y composición farmacéutica que lo comprende
AR115965A1 (es) Derivados heteroaromáticos de carboxamida como inhibidores de la calicreína plasmática
ECSP22026478A (es) Inhibidor de diacilglicerol aciltransferasa 2
BR112022005736A2 (pt) Compostos de azaindol carboxamida para o tratamento de infecções micobacterianas
BR112018000925A2 (pt) composto heterocíclico contendo nitrogênio
MX2020013811A (es) Compuestos.
PE20211454A1 (es) Derivados de imidazopiridina y su uso como medicamento
BR112022005723A2 (pt) Compostos de indol carboxamida e seu uso para o tratamento de infecções micobacterianas
CO2021000782A2 (es) Agentes inhibidores de ask1
GT200500214A (es) Amidas del acido 5 y 6-aminoalquil indol-2-carboxilico 3-sustituidas y análogos relacionados como inhibidores de la caseína cinasa epsilon

Legal Events

Date Code Title Description
B10A Cessation: cessation confirmed
B350 Update of information on the portal [chapter 15.35 patent gazette]